[{"id":"f33d52c2-9a8f-4b5c-acef-4121e6304fc8","acronym":"CA209-982","url":"https://clinicaltrials.gov/study/NCT03583086","created_at":"2021-01-18T17:37:36.257Z","updated_at":"2025-02-25T14:27:15.271Z","phase":"Phase 1/2","brief_title":"Phase I/II Eval Safety \u0026 Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic Tumors","source_id_and_acronym":"NCT03583086 - CA209-982","lead_sponsor":"Vanderbilt-Ingram Cancer Center","biomarkers":" EGFR • PD-L1 • BRAF • ROS1","pipe":"","alterations":" ","tags":["EGFR • PD-L1 • BRAF • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Fumena (vorolanib)"],"overall_status":"Completed","enrollment":" Enrollment 88","initiation":"Initiation: 07/10/2018","start_date":" 07/10/2018","primary_txt":" Primary completion: 02/21/2024","primary_completion_date":" 02/21/2024","study_txt":" Completion: 04/27/2024","study_completion_date":" 04/27/2024","last_update_posted":"2024-10-08"},{"id":"2dbed34d-5428-4bc0-85ff-a9b134ca1b93","acronym":"","url":"https://clinicaltrials.gov/study/NCT01296581","created_at":"2021-01-18T05:16:10.054Z","updated_at":"2024-07-02T16:36:16.356Z","phase":"Phase 1","brief_title":"Safety Study of X-82 in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT01296581","lead_sponsor":"Tyrogenex","biomarkers":" MUC16","pipe":" | ","alterations":" MUC16 elevation","tags":["MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MUC16 elevation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Fumena (vorolanib)"],"overall_status":"Completed","enrollment":" Enrollment 52","initiation":"Initiation: 02/01/2011","start_date":" 02/01/2011","primary_txt":" Primary completion: 01/01/2014","primary_completion_date":" 01/01/2014","study_txt":" Completion: 01/01/2017","study_completion_date":" 01/01/2017","last_update_posted":"2022-02-28"},{"id":"fa06bf79-998e-40a1-8904-0defc1d20284","acronym":"CM082-CA-IV-401","url":"https://clinicaltrials.gov/study/NCT03848611","created_at":"2021-01-18T18:59:47.736Z","updated_at":"2024-07-02T16:36:43.447Z","phase":"Phase 2","brief_title":"CM082 and JS001 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC).","source_id_and_acronym":"NCT03848611 - CM082-CA-IV-401","lead_sponsor":"AnewPharma","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Loqtorzi (toripalimab-tpzi) • Fumena (vorolanib)"],"overall_status":"Unknown status","enrollment":" Enrollment 20","initiation":"Initiation: 04/02/2019","start_date":" 04/02/2019","primary_txt":" Primary completion: 02/01/2021","primary_completion_date":" 02/01/2021","study_txt":" Completion: 09/01/2021","study_completion_date":" 09/01/2021","last_update_posted":"2020-07-09"},{"id":"0014cdbd-040f-4762-a144-d921d5f4323b","acronym":"","url":"https://clinicaltrials.gov/study/NCT03602547","created_at":"2021-01-18T17:43:20.888Z","updated_at":"2024-07-02T16:36:58.381Z","phase":"Phase 2","brief_title":"Study of the Combination of CM082 With JS001 in Patients With Advanced Mucosal Melanoma.","source_id_and_acronym":"NCT03602547","lead_sponsor":"AnewPharma","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Loqtorzi (toripalimab-tpzi) • Fumena (vorolanib)"],"overall_status":"Unknown status","enrollment":" Enrollment 40","initiation":"Initiation: 07/31/2018","start_date":" 07/31/2018","primary_txt":" Primary completion: 07/01/2019","primary_completion_date":" 07/01/2019","study_txt":" Completion: 06/01/2020","study_completion_date":" 06/01/2020","last_update_posted":"2019-07-05"}]